Company intelligence / Profile preview
HUYABIO International, LLC
San Diego, California, United States
- Ownership
- Private
- Employees
- ~118
- Development stage
- Other
01
Overview
HUYABIO’s lead drug HBI-8000 (chidamide, an HDAC inhibitor) is approved in China, in registration trials in Japan and Korea for lymphoma, and in Phase 3 trials for unresectable melanoma; other assets include multiple small molecule therapeutics at clinical and preclinical stages targeting oncology and cardiovascular diseases
- Therapeutic areas
- OncologyCardiovascular
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Extensive collaborations with biopharmaceutical, academic and commercial organizations in China and globally
Beyond the preview
Go deeper on HUYABIO International, LLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HUYABIO International, LLC.